Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. (LYRA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
lyra · stock forecast · 5 analysts (3M) · FMP · updated Mar 20, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Hold
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.50
Consensus
$0.50
-23.1% upside
Low
$0.50
Median: $0.5 · Last Close: $0.65
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.68 | ↑ 5.00% |
1-day model range: $0.67–$0.69. Peak: $0.69 (+5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LYRA · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-14 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-06-10 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2025-03-14 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-08-15 | HC Wainwright & Co. | Maintains | Neutral→Neutral |
| 2024-05-07 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2024-05-07 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-05-06 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2024-05-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-03-25 | B of A Securities | Maintains | Buy→Buy |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Lyra Therapeutics, Inc. (LYRA) stock. Of the recent 16 rating actions, 0 were upgrades and 3 were downgrades. 5 analysts currently cover LYRA.
Analyst Recommendation Trends
LYRA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 86.0% YoY
Revenue Next Year
$3M
↑ 237.5% YoY
EPS This Year
$-1.50
EPS Next Year
$-0.99
↓ 34.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast LYRA EPS of $-1.50 for the current fiscal year, based on estimates from 1 analysts. The LYRA revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LYRA stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LYRA price target is $0.50 (-23.1% upside), with an analyst consensus of Hold.
The LYRA short-term stock prediction for tomorrow is $0.68 (+5.00%).
Lyra Therapeutics, Inc. trades on NASDAQ under the ticker LYRA. The LYRA stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
LYRA forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month LYRA price target is $0.50, with a high forecast of $0.50 and a low of $0.50. The median price target is shown in the chart above when available. This implies -23.1% potential upside from the current price of $0.65.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.